Pacira BioSciences, Inc. (PCRX)
USD 25.75
(2.18%)
USD 25.75
(2.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 162.89 Million USD | 34.11% |
| 2022 | 144.77 Million USD | -16.01% |
| 2021 | 118.47 Million USD | 116.29% |
| 2020 | 71.42 Million USD | 52.61% |
| 2019 | 55.28 Million USD | 89.77% |
| 2018 | 33.05 Million USD | 245.9% |
| 2017 | -10.59 Million USD | 48.6% |
| 2016 | -17.86 Million USD | -408.82% |
| 2015 | 21.39 Million USD | 301.7% |
| 2014 | 5.09 Million USD | 89.56% |
| 2013 | -50.72 Million USD | 3.67% |
| 2012 | -44.54 Million USD | -69.15% |
| 2011 | -34.23 Million USD | -60.6% |
| 2010 | -19.11 Million USD | 26.13% |
| 2009 | -24.11 Million USD | 40.73% |
| 2008 | -41.53 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 49.83 Million USD | 40.86% |
| 2024 Q1 | 33.54 Million USD | -32.54% |
| 2023 Q3 | 37.74 Million USD | -4.27% |
| 2023 Q4 | 52.45 Million USD | 38.97% |
| 2023 FY | - USD | 34.11% |
| 2023 Q2 | 39.42 Million USD | 48.95% |
| 2023 Q1 | 26.47 Million USD | -15.78% |
| 2022 Q4 | 31.43 Million USD | -0.88% |
| 2022 Q2 | 32.77 Million USD | -19.54% |
| 2022 Q1 | 40.73 Million USD | -22.47% |
| 2022 FY | - USD | -16.01% |
| 2022 Q3 | 31.7 Million USD | -3.24% |
| 2021 Q2 | 37.05 Million USD | 43.8% |
| 2021 Q1 | 25.76 Million USD | -9.54% |
| 2021 Q4 | 52.53 Million USD | 46.27% |
| 2021 Q3 | 35.91 Million USD | -3.08% |
| 2021 FY | - USD | 116.29% |
| 2020 Q1 | 15.25 Million USD | -12.28% |
| 2020 FY | - USD | 52.61% |
| 2020 Q2 | 1.53 Million USD | -89.97% |
| 2020 Q3 | 24.01 Million USD | 1469.41% |
| 2020 Q4 | 28.48 Million USD | 18.63% |
| 2019 Q4 | 17.38 Million USD | 79.09% |
| 2019 Q2 | 15.26 Million USD | 134.7% |
| 2019 Q3 | 9.7 Million USD | -36.41% |
| 2019 FY | - USD | 89.77% |
| 2019 Q1 | 6.5 Million USD | -53.96% |
| 2018 Q3 | 9.29 Million USD | -12.34% |
| 2018 Q1 | -3.03 Million USD | -130.85% |
| 2018 FY | - USD | 245.9% |
| 2018 Q4 | 14.12 Million USD | 52.04% |
| 2018 Q2 | 10.6 Million USD | 448.91% |
| 2017 FY | - USD | 48.6% |
| 2017 Q4 | 9.84 Million USD | 1126.4% |
| 2017 Q3 | 803 Thousand USD | 112.06% |
| 2017 Q2 | -6.66 Million USD | 37.3% |
| 2017 Q1 | -10.62 Million USD | -397.56% |
| 2016 Q4 | -2.13 Million USD | 87.73% |
| 2016 Q2 | -3.1 Million USD | -393.38% |
| 2016 Q1 | 1.05 Million USD | 246.74% |
| 2016 FY | - USD | -408.82% |
| 2016 Q3 | -17.4 Million USD | -460.63% |
| 2015 Q1 | 3.37 Million USD | -57.89% |
| 2015 Q4 | -721 Thousand USD | -109.07% |
| 2015 FY | - USD | 301.7% |
| 2015 Q3 | 7.94 Million USD | 70.29% |
| 2015 Q2 | 4.66 Million USD | 38.15% |
| 2014 Q4 | 8.02 Million USD | 435.65% |
| 2014 FY | - USD | 89.56% |
| 2014 Q3 | 1.49 Million USD | 406.34% |
| 2014 Q2 | -489 Thousand USD | 94.71% |
| 2014 Q1 | -9.25 Million USD | -14.42% |
| 2013 Q4 | -8.08 Million USD | 29.27% |
| 2013 Q1 | -17.14 Million USD | -8.7% |
| 2013 FY | - USD | 3.67% |
| 2013 Q2 | -11.95 Million USD | 30.27% |
| 2013 Q3 | -11.43 Million USD | 4.4% |
| 2012 Q2 | -5.15 Million USD | 45.48% |
| 2012 Q1 | -9.45 Million USD | -21.1% |
| 2012 Q3 | -14.61 Million USD | -183.7% |
| 2012 Q4 | -15.77 Million USD | -7.89% |
| 2012 FY | - USD | -69.15% |
| 2011 FY | - USD | -60.6% |
| 2011 Q1 | -4.95 Million USD | 8.36% |
| 2011 Q2 | -8.93 Million USD | -80.35% |
| 2011 Q3 | -7.65 Million USD | 14.32% |
| 2011 Q4 | -7.8 Million USD | -1.91% |
| 2010 Q4 | -5.4 Million USD | 0.13% |
| 2010 Q3 | -5.41 Million USD | -27.86% |
| 2010 Q2 | -4.23 Million USD | -18.46% |
| 2010 Q1 | -3.57 Million USD | 54.88% |
| 2010 FY | - USD | 26.13% |
| 2009 Q3 | -4.13 Million USD | 0.0% |
| 2009 Q4 | -7.92 Million USD | -91.73% |
| 2009 FY | - USD | 40.73% |
| 2008 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 202.546% |
| PainReform Ltd. | -9.56 Million USD | 1802.341% |
| Alvotech | -484.86 Million USD | 133.597% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 47.168% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | -49.009% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -13681.472% |
| Journey Medical Corporation | 1.92 Million USD | -8379.802% |
| Dynavax Technologies Corporation | 9.66 Million USD | -1585.258% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 208.52% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 245.4 Million USD | 33.62% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 4359.393% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 4359.393% |
| SCYNEXIS, Inc. | 73.47 Million USD | -121.692% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 3967.569% |
| Silver Spike Investment Corp. | 7.34 Million USD | -2119.272% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 7028.809% |
| Alpha Teknova, Inc. | -25.53 Million USD | 737.836% |
| Safety Shot Inc | -12.18 Million USD | 1436.845% |
| Procaps Group, S.A. | 104.02 Million USD | -56.591% |
| Cosmos Health Inc. | -17.06 Million USD | 1054.747% |
| Theratechnologies Inc. | -10.31 Million USD | 1679.562% |
| Harrow Health, Inc. | 9.72 Million USD | -1575.378% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 3699.934% |
| Biofrontera Inc. | -18.45 Million USD | 982.767% |
| DURECT Corporation | -24.68 Million USD | 759.93% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -65.778% |
| Cronos Group Inc. | -72.14 Million USD | 325.779% |
| OptiNose, Inc. | -15.55 Million USD | 1147.367% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 117.613% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 551.463% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -520.179% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -352.102% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 4253.042% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 23015.805% |
| Radius Health, Inc. | 38.31 Million USD | -325.208% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 5166.672% |
| ProPhase Labs, Inc. | -14.82 Million USD | 1198.651% |
| Phibro Animal Health Corporation | 84.6 Million USD | -92.534% |
| Procaps Group S.A. | 104.02 Million USD | -56.591% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 2039.019% |
| Viatris Inc. | 3.51 Billion USD | 95.368% |
| Rockwell Medical, Inc. | -4.69 Million USD | 3570.324% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 16196.542% |
| SIGA Technologies, Inc. | 84.15 Million USD | -93.558% |
| Tilray Brands, Inc. | -72.84 Million USD | 323.628% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -19961.207% |
| Shineco, Inc. | -26.55 Million USD | 713.458% |
| PetIQ, Inc. | 81.48 Million USD | -99.908% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 4602.868% |
| Incannex Healthcare Limited | -18.5 Million USD | 980.334% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 60.851% |
| Alimera Sciences, Inc. | 7.27 Million USD | -2138.826% |
| Assertio Holdings, Inc. | -222.44 Million USD | 173.23% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 4181.968% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 1069.394% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 913.233% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 209.235% |
| Hempacco Co., Inc. | -12.77 Million USD | 1375.296% |
| Talphera, Inc. | -9.84 Million USD | 1755.121% |
| Alvotech | -484.86 Million USD | 133.597% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | -110.184% |
| Lantheus Holdings, Inc. | 491 Million USD | 66.824% |
| Currenc Group, Inc. | -1.9 Million USD | 8670.937% |
| Kamada Ltd. | 21.53 Million USD | -656.464% |
| Indivior PLC | 66 Million USD | -146.814% |
| Evoke Pharma, Inc. | -7.29 Million USD | 2333.824% |
| Flora Growth Corp. | -45.87 Million USD | 455.128% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 913.233% |
| Evolus, Inc. | -41.81 Million USD | 489.613% |
| HUTCHMED (China) Limited | 25.52 Million USD | -538.111% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 32.538% |
| Akanda Corp. | -27.73 Million USD | 687.319% |